EULAST II

• Research type

  Research Study

• Full title

  European Long-acting Antipsychotics in Schizophrenia Trial-II

• IRAS ID

  312388

• Contact name

  Lyliana Nasib

• Contact email

  L.Nasib@umcutrecht.nl

• Sponsor organisation

  The European Group for Research in Schizophrenia (EGRIS)

• Duration of Study in the UK

  3 years, 2 months, 31 days

• Research summary

  Multicenter, multinational long-term follow-up cohort study. The current EULAST-II
  cohort study consists of one follow-up visit, which will be conducted at least three years after the last EULAST-I clinical trial visit of the individual patient.
  The primary objective of this study is to assess which baseline EULAST-I clinical trial baseline characteristics predict healthcare utilization (defined as number of days hospitalized) over a period of 3 - 10 years (since the EULAST-I clinical trial baseline visit). Secondary objectives concern long-term data on neuropsychiatric diagnoses, social functioning, quality of life, extrapyramidal symptoms, alcohol and drugs use, number of hospitalizations, medication use and medical history.

• REC name

  South Central - Berkshire Research Ethics Committee

• REC reference

  22/SC/0176

• Date of REC Opinion

  21 Jul 2022

• REC opinion

  Further Information Favourable Opinion